Longitudinal trends and predictors of statin use among patients with diabetes

被引:14
作者
Brennan, Meghan B. [1 ]
Huang, Elbert S. [2 ]
Lobo, Jennifer M. [3 ]
Kang, Hyojung [4 ]
Guihan, Marylou [5 ,6 ]
Basu, Anirban [7 ,8 ]
Sohn, Min-Woong [3 ]
机构
[1] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA
[2] Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA
[3] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA
[4] Univ Virginia, Sch Engn, Dept Syst & Informat Engn, Charlottesville, VA USA
[5] Hines VA Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL USA
[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[7] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA
[8] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA
基金
美国国家卫生研究院; 美国医疗保健研究与质量局;
关键词
HMG-CoA reductase inhibitors; Racial disparities; Cholesterol treatment guidelines; Temporal trends; Diabetes; CARDIOVASCULAR-DISEASE; RACIAL DISPARITIES; PRIMARY PREVENTION; NATIONAL-HEALTH; CARE; VETERANS; ADULTS; ATORVASTATIN; PREVALENCE; OUTCOMES;
D O I
10.1016/j.jdiacomp.2017.09.014
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Aim: Statins reduce morbidity and mortality among patients with diabetes, but their use remains suboptimal. Understanding trends in statin use may inform strategies for improvement. Methods: We enrolled a national, retrospective cohort of 899,664 veterans aged >= 40 years with diabetes in 2003. We followed them through 2011, dividing the nine-year follow-up into 90-day periods. For each period, we determined statin use, defined as possession of >= 30-day supply. We examine factors associated with statin uptake among baseline non-users with a multivariate model. Results: Baseline prevalence of statin use was 43%, increased by 1.8% per period (p for trend < 0.001), and reached a maximum of similar to 59%. Stalin use among non-Hispanic racial/ethnic minorities lagged behind their white counterparts. Among baseline non-users, statin use was 9% after Year 1 and reached 36% by Year 9. Factors associated with statin uptake included use of hypoglycemic agents, HbA1c between 7 and 8.9% (53-74 mmol/mol), hypertension, heart failure, peripheral vascular disease, and Hispanic ethnicity. Conclusion: Statin use is slowly increasing among patients with diabetes, and at varying rates within subgroups of this population. Policies that prioritize these subgroups for statin promotion may help guide future, intervention based research to increase compliance with current guidelines. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 30 条
[1]
Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study [J].
Ab, Elisabeth ;
Denig, Petra ;
van Vliet, Ton ;
Dekker, Janny H. .
BMC FAMILY PRACTICE, 2009, 10
[2]
Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011-2012 [J].
Adedinsewo, Demilade ;
Taka, Nchang ;
Agasthi, Pradyumna ;
Sachdeva, Rajesh ;
Rust, George ;
Onwuanyi, Anekwe .
CLINICAL CARDIOLOGY, 2016, 39 (09) :491-496
[3]
Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort [J].
Bai, Johnny W. ;
Boulet, Genevieve ;
Halpern, Elise M. ;
Lovblom, Leif E. ;
Eldelekli, Devrim ;
Keenan, Hillary A. ;
Brent, Michael ;
Paul, Narinder ;
Bril, Vera ;
Cherney, David Z. I. ;
Weisman, Alanna ;
Perkins, Bruce A. .
CARDIOVASCULAR DIABETOLOGY, 2016, 15
[4]
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel [J].
Banach, Maciej ;
Rizzo, Manfredi ;
Toth, Peter P. ;
Farnier, Michel ;
Davidson, Michael H. ;
Al-Rasadi, Khalid ;
Aronow, Wilbert S. ;
Athyros, Vasilis ;
Djuric, Dragan M. ;
Ezhov, Marat V. ;
Greenfield, Robert S. ;
Hovingh, G. Kees ;
Kostner, Karam ;
Serban, Corina ;
Lighezan, Daniel ;
Fras, Zlatko ;
Moriarty, Patrick M. ;
Muntner, Paul ;
Goudev, Assen ;
Ceska, Richard ;
Nicholls, Stephen J. ;
Broncel, Marlena ;
Nikolic, Dragana ;
Pella, Daniel ;
Puri, Raman ;
Rysz, Jacek ;
Wong, Nathan D. ;
Bajnok, Laszlo ;
Jones, Steven R. ;
Ray, Kausik K. ;
Mikhailidis, Dimitri P. .
ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (01) :1-23
[5]
Statin safety: An overview and assessment of the data-2005 [J].
Bays, H .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :6C-26C
[6]
Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease [J].
Beishuizen, ED ;
Van de Ree, MA ;
Jukema, JW ;
Tamsma, JT ;
Van der Vijver, JCM ;
Meinders, AE ;
Putter, H ;
Huisman, MV .
DIABETES CARE, 2004, 27 (12) :2887-2892
[7]
Statins for Prevention of Cardiovascular Disease in Adults Evidence Report and Systematic Review for the US Preventive Services Task Force [J].
Chou, Roger ;
Dana, Tracy ;
Blazina, Ian ;
Daeges, Monica ;
Jeanne, Thomas L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (19) :2008-2024
[8]
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[9]
Dudl RJ, 2009, AM J MANAG CARE, V15, pE88
[10]
Comorbidity measures for use with administrative data [J].
Elixhauser, A ;
Steiner, C ;
Harris, DR ;
Coffey, RN .
MEDICAL CARE, 1998, 36 (01) :8-27